Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT02447302 is registered in ClinicalTrials.gov with Arena Pharmaceuticals as lead sponsor.

NCT NCT02447302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02447302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Arena Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
October 15, 2015
Completion date
February 14, 2018
Enrollment
156 (actual)
Sites
134

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis